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Abstract: In Belgium, the incorporation of phages into magistral preparations for human application
has been permitted since 2018. The stability of such preparations is of high importance to guarantee
quality and efficacy throughout treatments. We evaluated the ability to preserve infectivity of four
different phages active against three different bacterial species in five different buffer and infusion
solutions commonly used in medicine and biotechnological manufacturing processes, at two different
concentrations (9 and 7 log pfu/mL), stored at 4 ◦C. DPBS without Ca2+ and Mg2+ was found to
be the best option, compared to the other solutions. Suspensions with phage concentrations of
7 log pfu/mL were unsuited as their activity dropped below the effective therapeutic dose (6–9 log
pfu/mL), even after one week of storage at 4 ◦C. Strong variability between phages was observed,
with Acinetobacter baumannii phage Acibel004 being stable in four out of five different solutions. We
also studied the long term storage of lyophilized staphylococcal phage ISP, and found that the titer
could be preserved during a period of almost 8 years when sucrose and trehalose were used as
stabilizers. After rehydration of the lyophilized ISP phage in saline, the phage solutions remained
stable at 4 ◦C during a period of 126 days.
Keywords: phage; API; magistral preparation; buffers; infusion solutions; infectivity; titer; stor-
age; lyophilization
1. Introduction
The Federal Agency for Medicines and Health Products (FAMHP) in Belgium gave
positive advice on the use of single bacteriophages (phages) as active pharmaceutical ingre-
dients (APIs) in magistral preparations produced by hospital pharmacies, from January
2018 onwards [1]. This opened the path to gradual acceptance of phage therapy as a valid
alternative or complementary therapy to antibiotics. In order to keep up with the demand
for personalized phage applications, sufficient data on formulation and stability of phage
therapeutic APIs and magistral preparations are required.
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In Eastern European countries, where phage therapy forms part of conventional
medicine, therapeutic phage preparations are produced most often as liquid formulations
and their storage period at 4 ◦C is limited to a maximum of two years [2,3].
A number of studies have addressed the optimal storage conditions of phages to pre-
serve the phage titer, i.e., the phage infectivity, over long periods of time [2,4,5]. In general,
tailed phages tend to be relatively stable at 4–80 ◦C and in liquid nitrogen, according to
Ackermann [6], but this stability is largely phage species dependent [7–9]. Lyophilisation
has been widely recognized as a means to stabilize biologicals and pharmaceutical com-
pounds [10], and is a standard procedure in culture collections for the long term storage of
bacterial cells and phages. Phages can be preserved also by spray-drying [11–14]. Either
lyophilized or freeze-dried phages can be considered as a single form of pharmaceutical
formulation, but they can also be used further in more innovative technologies, such as
encapsulation in micro or nanoparticles, liposomes, electrospun fibers, or immobilized on
different surfaces, including nanofibers, hydrogels or nylon sutures [15–24].
In this study, we assessed the stability of phages in formulations that can be used
for production of phage APIs and magistral preparations. We evaluated, specifically, the
infectivity of four phages (Acibel004, PNM, 14/1 and ISP) after storage at 4 ◦C in five
different solutions commonly used in biotech, industry and medicine (5% glucose, 0.9%
NaCl, Hartmann and Dulbecco’s phosphate-buffered saline (DPBS) with and without Ca2+
and Mg2+). The infectivity of the phages stored at concentrations of 9 and 7 log pfu/mL was
determined after a storage period of up to 554 days by double-agar overlay method [25].
In addition, we assessed stability of Staphylococcus aureus phage ISP after storage
for almost 8 years as a lyophilizate prepared with two different stabilizers (sucrose or
trehalose), at four different concentrations (0.3, 0.5, 0.8 and 1.0 M). Finally, we checked how
ISP infectivity decreased after resuspension of these lyophilizates in saline after storage for
up to 126 days.
2. Materials and Methods
2.1. Phages and Propagating Bacterial Host Strains
Phage Acibel004 and its propagating bacterial strain Acinetobacter baumannii 070517/
0072 were received from Queen Astrid Military Hospital, Brussels, Belgium. Three other
phages, PNM, 14/1, and ISP, along with their propagating bacterial strains Pseudomonas
aeruginosa CN573 and Staphylococcus aureus ATCC 6538, respectively, were part of the
collection of Ghent University and were originally acquired from the Eliava Institute
of Bacteriophages, Microbiology and Virology (EIMBV), Tbilisi, Georgia, and the State
Institute of Genetics and Selection of Industrial Microorganisms (SIGSIM), Moscow, Russia.
The list of the phages, their bacterial hosts, and characteristics are presented in Table 1.
Table 1. Name, bacterial host strain, morphology, genus, particle size, genome size and National Center for Biotechnology
Information (NCBI) genome accession number of each phage.











Myovirus Myoviridae/Saclayvirus 70–105 99.7 KJ473422
PNM Pseudomonasaeruginosa CN 573 Podovirus
Autographiviridae/
Phikmvvirus 60–10 42.4 Unpublished data
14/1 Pseudomonasaeruginosa CN 573 Myovirus Myoviridae/Pbunavirus 78–100 66.1 NC_011703
ISP Staphylococcusaureus ATCC6538 Myovirus Herelleviridae/Twortvirus 90–175 138.4 NC_047720
2.2. Production of Phage Stocks
Phage stocks were prepared as described previously, using the double agar overlay
method with minor modifications [25]. Briefly, phages and bacteria were mixed at a
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pre-defined ratio calculated to produce a maximum density of single plaques, creating a
“web-like” picture on the plate. To this, 3.5 mL of liquid lysogeny broth (LB broth, VWR
Chemicals, Leuven, Belgium) supplemented with 0.6% agar was added, and the mixture
was poured onto a preset agar plate to create a double-layer. After overnight incubation, the
top agar layer was scraped off and collected in 50 mL centrifuge tubes (Beckman Coulter,
Brea, CA, USA). After a first centrifugation step at 6000× g for 20 min, the supernatant
was filtered through 0.45 and 0.22 µm membrane filters (Millex, Merck Millipore, Cork,
Ireland). Phages were then pelleted by high-speed centrifugation at 35,000× g for 1 h.
The resulting pellet was resuspended overnight in DPBS without (w/o) Ca2+ and Mg2+
(Lonza, Verviers, Belgium). The exact titers of the phage stocks were defined by double
agar overlay method [25].
2.3. Stability Experiments
Phage stocks were diluted to 10 mL, in triplicate in five different solutions to produce
different starting concentrations, i.e., 9 and 7 log pfu/mL in 15 mL polypropylene tubes
(GreinerBioOne, Vilvoorde, Belgium), and stored at 4 ◦C.
Five different solutions used were: 5% glucose infusion solution (Fresenius Kabi,
Schelle, Belgium); 0.9% NaCl infusion solution (Fresenius Kabi, Schelle, Belgium); Hart-
mann infusion solution (Baxter, Lessines, Belgium); DPBS supplemented with (w/) Ca2+
and Mg2+ (Lonza Biosciences, Verviers, Belgium); and without (w/o) Ca2+ and Mg2+
(Lonza Biosciences, Verviers, Belgium). Table 2 summarizes the detailed composition and
characteristics of the five storage solutions. Phage infectivity was tested by determination
of phage titer with the double agar overlay method on propagating bacterial strains, as
described previously [25].
Table 2. Information on the solutions used in the stability experiment.




for injection glucose 5% w/v Water for injection 3.5–6.5 Intravenous infusion Fresenius Kabi





4.5–7.0 Intravenous infusion Fresenius Kabi
Hartmann’s infusion
solution
Sodium Lactate 3.17 g/L,
Sodium Chloride 6.0 g/L,
Potassium Chloride 0.4 g/L,






5.0–7.0 Intravenous infusion Fresenius Kabi
DPBS w/ Ca2+ and
Mg2+
Potassium chloride 0.2 g/L,
Monopotassium phosphate 0.2 g/L,
Sodium chloride 8 g/L,
Disodium hydrogen phosphate
heptahydrate 2.1 g/L
Water for injection 7.0–7.6 Research andmanufacturing use Corning Inc
DPBS w/o Ca2+ and
Mg2+
Potassium chloride 0.2 g/L,
Monopotassium phosphate 0.2 g/L,
Sodium chloride 8 g/L,
Disodium hydrogen phosphate
heptahydrate 2.1 g/L,
Calcium chloride 0.1 g/L,
Magnesium chloride hexahydrate 0.1 g/L
Water for injection 7.0–7.6 Research andmanufacturing use
Lonza Group
AG
2.4. Testing Stability of ISP Lyophilizates
Phage ISP was lyophilized on 21 December 2010 as described by Merabishvili et al. [2].
On the 25 October 2018, after a storage period of nearly 8 years, the lyophilized samples
were resuspended in 1 mL of 0.9% NaCl solution after which the infectivity of the phages
was immediately determined by double agar overlay method. Resuspended phages were
stored at 4 ◦C and infectivity was again checked after 126 days. Each test was performed in
triplicate for each lyophilized phage sample.
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3. Results
The first part of the study evaluated the long term storage of phages at 4 ◦C in different
solutions. The original stocks of four phages, A. baumannii phage Acibel004, P. aeruginosa
phages PNM and 14/1, and S. aureus phage ISP, were diluted to two different starting
concentrations (9 and 7 log pfu/mL), in each five different solutions, 5% glucose, 0.9%
NaCl, Hartmann solution, DPBS with and without Ca2+ and Mg2+, and stored at 4 ◦C.
Phage titers (infectivity) of all suspensions were determined after 1, 3, 7, 10, 14, 21 and
35 days. The infectivity of the 9 log pfu/mL phage suspensions of Acibel004, PNM, 14/1
and ISP were analyzed again after 554, 286, 243 or 282 days, respectively.
Phage Acibel004 (Myovirus) was found to maintain its infectivity in all storage solu-
tions after 554 days when stored at a concentration of 9 log pfu/mL, except 5% glucose
(Figure 1, Table S1). In 5% glucose the infectivity declined immediately after dilution
leading up to a 100-fold reduction after 30 days and this titer was maintained after 64 days
too. Acibel004 was also unstable in 5% glucose at the lower starting concentration (7 log
pfu/mL), resulting in complete inactivation after 7 days. The lower starting concentration
also resulted in instability in the other four solutions, such that after 35 days the titer had
already decreased approximately 100-fold in all solutions (Figure 1, Table S1).




Figure 1. Stability over time of the infectivity of different phages, stored at 4 °C at two different concentrations: 9 log 
pfu/mL (solid lines); 7 log pfu/mL (dotted lines). Phages were suspended in 5% glucose (green), 0.9% NaCl (blue), 
Hartmann solution (black), DPBS w/ Ca2+ and Mg2+ (red), and DPBS w/o Ca2+ and Mg2+ (yellow). Infectivity was determined 
by the double agar overlay method. The results are the mean values of triplicate samples of each phage at each 
concentration in each solution. Standard deviations are indicated. Average standard deviations of Acibel004; 14/1; PNM 
and ISP are 0.06; 0.15; 0.26 and 0.18, respectively. For phage ISP results were from an 8.8–8.9 log pfu/mL sample. 
P. aeruginosa phage PNM (Podovirus) was inactivated immediately after dilution in 
5% glucose. In the other four solutions, at a concentration of 9 log pfu/mL there was no 
loss of infectivity after a storage period of 35 days. After 286 days, infectivity remained 
unaffected when stored in DPBS w/ and w/o Ca2+ and Mg2+. However, it dropped with 
one and two logs when stored in 0.9% NaCl and Hartmann solutions, respectively. From 
a starting concentration of 7 log pfu/mL, we observed a general decrease in infectivity of 
PNM to approximately 3 or 4 log pfu/mL after 35 days of storage at 4 °C, irrespective of 
the storage solution.  
Phage 14/1 (Myovirus) showed some resistance towards 5% glucose. At 9 and 7 log 
pfu/mL starting concentrations, no immediate decline in infectivity was observed, 
although a gradual decline was observed over 243 and 56 days, respectively. In the other 
four solutions, after the total storage period of 243 days the best results were obtained 
with DPBS w/ and w/o Ca2+ and Mg2+ (log pfu/mL reduction of 1.03 and 0.66; Figure 1, 
Table S1). Again, when the phages were stored at a starting concentration of 7 log pfu/mL, 
the titers started to drop after 28 days of storage, falling to 1–2 log pfu/mL after 243 days.  
For S. aureus phage ISP (Myovirus), dilution in 5% glucose had a similar effect as for 
phage PNM, causing complete and immediate inactivation at both starting 
concentrations. In other solutions, when stored at a starting concentration close to 9 log 
i r ilit over time of the infectivity of different phages, stored at 4 ◦C at two different concentrations: 9 log pfu/mL
(solid lines); 7 log pfu/mL (dotted lines). Phages were suspended in 5% glucose (green), 0.9% NaCl (blue), Hartmann
solution (black), DPBS w/ Ca2+ and Mg2+ (red), and DPBS w/o Ca2+ and Mg2+ (yellow). Infectivity was determined by the
double agar overlay method. The results are the mean values of triplicate samples of each phage at each concentration in
each solution. Standard deviations are indicated. Average standard deviations of Acibel004; 14/1; PNM and ISP are 0.06;
0.15; 0.26 and 0.18, respectively. For phage ISP results were from an 8.8–8.9 log pfu/mL sample.
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P. aeruginosa phage PNM (Podovirus) was inactivated immediately after dilution in
5% glucose. In the other four solutions, at a concentration of 9 log pfu/mL there was no
loss of infectivity after a storage period of 35 days. After 286 days, infectivity remained
unaffected when stored in DPBS w/ and w/o Ca2+ and Mg2+. However, it dropped with
one and two logs when stored in 0.9% NaCl and Hartmann solutions, respectively. From a
starting concentration of 7 log pfu/mL, we observed a general decrease in infectivity of
PNM to approximately 3 or 4 log pfu/mL after 35 days of storage at 4 ◦C, irrespective of
the storage solution.
Phage 14/1 (Myovirus) showed some resistance towards 5% glucose. At 9 and
7 log pfu/mL starting concentrations, no immediate decline in infectivity was observed,
although a gradual decline was observed over 243 and 56 days, respectively. In the other
four solutions, after the total storage period of 243 days the best results were obtained
with DPBS w/ and w/o Ca2+ and Mg2+ (log pfu/mL reduction of 1.03 and 0.66; Figure 1,
Table S1). Again, when the phages were stored at a starting concentration of 7 log pfu/mL,
the titers started to drop after 28 days of storage, falling to 1–2 log pfu/mL after 243 days.
For S. aureus phage ISP (Myovirus), dilution in 5% glucose had a similar effect as
for phage PNM, causing complete and immediate inactivation at both starting concentra-
tions. In other solutions, when stored at a starting concentration close to 9 log pfu/mL
(8.7–8.8 log pfu/mL), a slight decrease in infectivity was observed after a period of 282 days,
with a maximum decrease of one log pfu/mL in Hartmann solution (Figure 1, Table S1).
As with the other phages, storage at 7 log pfu/mL generally resulted in a major decrease in
infectivity starting after 14 days in all storage solutions and declining below the therapeutic
titer after 34 days.
Considering the four phages, the best results were obtained with DPBS w/o Ca2+ and
Mg2+. The 5% Glucose solution (pH range of 3.5–6.5) had the strongest detrimental impact
on the infectivity of the phages. Two phages, the podovirus PNM and a myovirus ISP were
inactivated immediately, while two other myoviruses, Acibel004 and 14/1, showed less
sensitivity to the 5% glucose solution and reduction in titer was more gradual. Higher
starting titers also improved stability in 5% glucose; whilst phage 14/1 showed complete
inactivation at 9 log pfu/mL after 243 days and phage Acibel004 showed a decrease of
2.2 logs after 64 days; when starting from the lower titer of 7 log pfu/mL both phages were
completely inactivated after only 7 (Acibel004) and 56 (14/1) days of storage, respectively.
In the second part of the study, we assessed the effect of prolonged storage of S.
aureus phage ISP [2] on infectivity. This phage had been lyophilized at four different
concentrations (0.3 M, 0.5 M, 0.8 M or 1.0 M) in two different stabilizers, sucrose and
trehalose. After storage as lyophilisates at 4 ◦C for nearly 8 years, the lyophilized phage
vials were resuspended in 1 mL of 0.9% NaCl solution. Immediately after resuspension, the
infectivity of the phages was determined. The same phage suspensions were then retested
after further storage at 4 ◦C for 126 days. As only a restricted number of samples were
available, only one copy of each sample was tested after 8 years.
Previous data show that immediately after lyophilization, a decrease in phage infec-
tivity between 0.43 log (0.8 M of sucrose) and 1.40 log (0.3 M of sucrose) was observed [2].
After storage for 27 months, a further, but not significant, minor decrease of 0.05–0.32 logs
was observed [2]. Overall, relative to the initial titer of 9 log pfu/mL (before lyophilization),
the best results were obtained with 0.8 M and 1.0 M sucrose and 1.0 M trehalose. In this
study, after nearly 8 years of storage at 4 ◦C, we did not identify any further significant
decrease in infectivity for all phage lyophilizates, except for the 0.8 M trehalose sample
(Figure 2, Table S2), when reduction equaled to 1.75 log pfu/mL. However, as only one
lyophilizate sample was tested no solid conclusion could be made on non-stability of the
phage titer at this particular concentration of the stabilizer.




Figure 2. Stability over time of the infectivity of phage ISP, lyophilized at 9 log pfu/mL, in two different stabilizers (sucrose 
and trehalose) at four different concentrations (0.3 M, 0.5 M, 0.8 M and 1.0 M) and stored at 4 °C, the last samples are 
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reproduced from Merabishvili et al. [2]. The results are the mean values of triplicate samples for all samples, except the 8 
year old samples, for which three titrations performed done on single samples. Standard deviations are indicated. 
After resuspending the lyophilized phage vials in saline, we assessed the infectivity 
during further storage at 4 °C for 126 days (Figure 3, Table S3). Infectivity remained quite 
stable for all samples with reductions in the range of 0.09–0.49 log pfu/mL.  
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Figure 3. Stability of the infectivity of phage ISP, lyophilized at 9 log pfu/mL in two different stabiliz rs (sucrose and
trehalose) at four different concentrations (0.3, 0.5, 0.8 and 1.0 M), after resuspension in saline and storage at 4 ◦C for
126 days. The results are the mean values of three titrations. Sta ard eviations are indicated.
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4. Discussion
Phage therapy is increasingly being considered as a means to treat bacterial infections
in Western medicine [26–28]. In Belgium, it has been possible to use phages as APIs in
preparations that can be tailored to the infecting agent and the needs of the patient since
2018 [1]. Once produced as APIs, phages become available to pharmacies where they can
be used as components of magistral preparations based on a medical doctor’s prescription
(currently restricted only to hospital pharmacies).
Ideally, a bank of therapeutically important and thoroughly characterized phages
should become available from which infection-tailored cocktails can be composed ad
hoc [29]. However, this requires phages to be stored for prolonged periods. The incorpora-
tion of phages into such collections could be based on a number of requirements formulated
by a consortium of phage experts [30]. The most important characteristics include safety
and efficacy based on sequence analysis of the phage genomes and assessment of their host
range profiles against a collection of reference and current clinical bacterial strains [30–32].
A bank with such strains should be regularly updated based on the state of the art from
the clinical sector [33,34]. Different methods are available for storing phages in therapeutic
phage banks for at least five years. Methods that have been used for almost a century
and have been considered “gold standards” for use since their discovery include storage
in liquid formulations at 4 ◦C, lyophilization at 4 ◦C or room temperature, and freezing
with glycerol at −80 ◦C [7,35–38]. A variety of pharmaceutical formulations can be used
for the production of APIs and/or the final phage products, based on conventional and
innovative platforms [39,40]. Following the Belgian “magistral preparation” pathway
(compounding pharmacies in the US), the final phage products that will be used in patients
are made by hospital pharmacists. Magistral phage preparations can be produced by
the dilution of liquid formulations of phage APIs into different infusion solutions to be
used intravenously, intramuscularly, etc. Phages can also be incorporated into creams or
gels for topical application. The same approach can be applied to dry formulations of
APIs (e.g., lyophilized), as they can be resuspended into different solutions and/or other
neutral carriers. Of importance for any pharmaceutical agent is the maintenance of its
efficacy during different stages of production and storage processes. This is especially
important for complex infective agents such as phages. The infectivity of the ready-to-use
magistral preparation should be guaranteed for at least several days, but preferably weeks
or months, to ascertain that prolonged series of administration can be carried out with the
same viable cocktail. Data on the stability of magistral preparations is of high importance
for pharmacists to manage their workflow, secure the quality of the preparations and to
effectively treat patients’ conditions. In the future, this data should, ideally, also be freely
available in databases.
In a recent high profile randomized controlled trial (RCT) on the efficacy and toler-
ability of P. aeruginosa phages to treat burn wounds (PhagoBurn trial), a lack of stability
of the formulated cGMP-certified (current Good Manufacturing Practice) phage products
was observed [41]. In the trial, patients were supposed to be treated with a phage cocktail
composed of 12 phages with an overall titer of 6 log pfu/mL, however, the phage product
had a reduced titer of only 1–2 log pfu/mL, much lower than the dose of phages needed
to successfully combat the infection upon the time of treatment. This contributed to the
partial failure of the trial, as investigators were unable to draw reliable conclusions on the
efficacy of this particular phage therapeutic.
We previously investigated phages from within the BFC2 cocktail which have already
been used for phage therapy in the Queen Astrid Military Hospital, Brussels. For those
phages we developed a quantitative qPCR [25]. In this study we selected these phages and
evaluated the potential of five different clinically relevant/commercially available buffer
and infusion solutions as the carriers for phage APIs and magistral preparations [2]. We
compared the solutions over prolonged storage at 4 ◦C with four different phages with
high therapeutic potential [42,43] against three different bacterial species and belonging
to two phage morphologies (three Myoviruses and one Podovirus). As an empirical rule,
Viruses 2021, 13, 865 8 of 11
the therapeutic titer of the phages should be in the range of 6–9 log pfu/mL [3,44–46].
Therefore, we decided to test two different concentrations within this range. Comparison
of two initial titers (9 log vs. 7 log pfu/mL) for storage of phages in liquid solutions at 4 ◦C
indicates that phages are more stable at high concentrations. Whereas the 9 log pfu/mL
remained relatively stable, the 7 log pfu/mL stocks rapidly deteriorated, resulting in loss of
infectivity (titer). Hence, precautions should be taken when working with low titer phage
preparations.
The observation that DPBS was the most stabilizing liquid for all phages also at the
low concentration of 7 log pfu/mL, might be explained largely by its neutral and stable pH
in contrast to the uncontrolled pH of saline and Hartmann solutions. The more acidic pH
of the other infusion solutions, especially of 5% glucose, resulted in greater reduction in
infectivity, whereby two phages were inactivated immediately (PNM and ISP), and two
phages (Acibel004 and 14/1) maintained their infectivity above an efficient therapeutic
titer for a maximum of 14 days. The optimal pH for storage should be determined for each
individual phage. Low pH has been shown to be deleterious for some phages [47–49] while
others are more stable at low pH [50]. Some phages are insensitive to pH, as reviewed
by Jonczyk et al. [47]. Phages Acibel004 and 14/1 showed relative resistance to lower pH
when their stability was evaluated in burn wound care products [48]. Phage 14/1 is a
representative of the genus Pbunavirus, which is characterized by high resistance to an acid
environment [51].
In this study DPBS with Ca2+ and Mg2+ (0.9 mM Ca2+ and 0.5 mM Mg2+) was found
to be slightly less effective than DPBS without Ca2+ and Mg2+ at maintaining the stability
of phages during long storage periods (except for ISP). The literature suggests an important
favorable role of Ca2+ and Mg2+ for phage stability; Adams [52] reported a stabilizing
role of Ca2+ (at concentrations > 0.1 mM) for Escherichia coli phage T5, while Thorne and
Holt [53] established improved stabilization of Bacillus phage CP-51 for a Ca2+ and Mg2+
concentrations of 10 mM. We, however, did not observe any significant beneficial effects of
increased Ca2+ and Mg2+ concentrations for all four phages when comparing the results
for DPBS with and without Ca2+ and Mg2+. This could be explained by the low, standard
concentration we used in contrast to the ones (10 mM) used in the abovementioned studies.
The high infectivity of the lyophilized S. aureus phage ISP, observed previously for
storage during a period of 27 months and prolonged in this study for a period of almost
8 years, indicates that this method is well-suited to preserving the infectivity of at least
some phages over very long periods. The stability of infectivity, maintained for 126 days
after rehydration in almost all lyophilizated samples, indicates that this method is suitable
for application in the production of APIs and magistral preparations.
5. Conclusions
In conclusion, a solution with stable and neutral pH and low ionic content (e.g., DPBS
without Ca2+ and Mg2+) was best suited for liquid storage of these four different phages at
concentrations used for production of APIs and magistral preparations, maintained at 4 ◦C.
Lyophilization with stabilizers, such as sucrose and trehalose, maintained the infectivity of
the phage during 8 years and up to 126 days after resuspension in saline. Despite these
promising results, indicating that many phages can maintain their infectivity at 4 ◦C in
various solutions, important variability between the four tested phages was observed. This
indicates that the concentrations of the stabilizer, the influence of pH and osmolality are
important parameters that need to be determined and optimized for individual phages.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/v13050865/s1, Table S1: Stability over time of the infectivity of different phages, expressed
as log pfu/mL stored at 4 ◦C at two different starting concentrations: 7 log pfu/mL and 9 log
pfu/mL; Table S2: Stability of ISP phage (9 log pfu/mL) in two different stabilizers after freeze-
drying procedure and storage at 4 ◦C; Table S3: Stability of resuspended ISP lyophilizates after
storage at 4 ◦C.
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